Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

The company will protect the branded anti-interleukin (IL)-12/23 biologic against sales erosion from pending biosimilars.

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...